Skip to main content

Advertisement

SpringerLink
Log in

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

An Erratum to this article was published on 04 April 2017

Abstract

Background

Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer.

Methods

A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed.

Results

Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months.

Conclusion

Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

ER:

Estrogen receptor

PgR:

Progesterone receptor

HER2:

Human epidermal growth factor receptor type 2

Ki67 LI:

Ki67 labeling index

IHC:

Immunohistochemistry

References

  1. Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29:2301–4.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.

    Article  CAS  PubMed  Google Scholar 

  3. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26:1948–55.

    Article  CAS  PubMed  Google Scholar 

  4. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99:1845–53.

    Article  CAS  PubMed  Google Scholar 

  5. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, et al. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Ann Oncol. 2016;27:806–12.

    Article  CAS  PubMed  Google Scholar 

  7. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol. 2007;18:45–51.

    Article  CAS  PubMed  Google Scholar 

  8. Sestak I, Cuzick J. Markers for the identification of late breast cancer recurrence. Breast Cancer Res. 2015;17:10.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, et al. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2015;. doi:10.1007/s12282-015-0649-0.

    PubMed Central  Google Scholar 

  10. Ahn SG, Lee HM, Cho SH, Bae SJ, Lee SA, Hwang SH, et al. The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence. PLoS One. 2013;8:e63510.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hayes DF. Clinical utility of genetic signatures in selecting adjuvant treatment: risk stratification for early vs. late recurrences. Breast. 2015;24(Suppl 2):S6–10.

    Article  PubMed  Google Scholar 

  12. Yamashita H, Ando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer. 2006;13:74–83.

    Article  PubMed  Google Scholar 

  13. Endo Y, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Iwasa M, et al. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol. 2011;16:512–8.

    Article  CAS  PubMed  Google Scholar 

  14. Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, et al. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005;7:R753–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, et al. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res. 2006;8:R48.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Johnston SR. Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: cotargeting signaling pathways. J Natl Cancer Inst. 2015;107:djv212. doi:10.1093/jnci/djv212.

    Article  PubMed  Google Scholar 

  17. Perez EA. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resist Updat. 2016;24:13–22.

    Article  PubMed  Google Scholar 

  18. Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, et al. Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Res Treat. 2011;43:89–95.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974–84.

    Article  CAS  PubMed  Google Scholar 

  20. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19:6389–97.

    Article  CAS  PubMed  Google Scholar 

  22. Cheng Q, Chang JT, Gwin WR, Zhu J, Ambs S, Geradts J, et al. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Res. 2014;16:407.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study was supported by a Grant-in-Aid for Scientific Research from the Japanese Breast Cancer Society.

Author information

Author notes

  1. Tomofumi Osako

    Present address: Kumamoto Shinto General Hospital, Kumamoto, Japan

Authors and Affiliations

  1. Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

    Akiko Ogiya & Kieko Yamazaki

  2. Division of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan

    Rie Horii

  3. Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan

    Tadahiko Shien & Yuichiro Miyoshi

  4. Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan

    Yoshiya Horimoto

  5. Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, Japan

    Norikazu Masuda & Hiroyuki Yasojima

  6. Department of Breast and Endocrine Surgery, Graduate School of Medical Science Kumamoto University, Kumamoto, Japan

    Touko Inao

  7. Breast Surgery, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan

    Mitsuchika Hosoda, Naoko Ishida & Hiroko Yamashita

  8. Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan

    Tomofumi Osako

  9. Department of Breast Surgery, NHO Hokkaido Cancer Center, Sapporo, Japan

    Masato Takahashi & Nobumoto Tomioka

  10. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Yumi Endo

Authors
  1. Akiko Ogiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kieko Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rie Horii
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tadahiko Shien
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiya Horimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Norikazu Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Touko Inao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mitsuchika Hosoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naoko Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tomofumi Osako
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masato Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yumi Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yuichiro Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hiroyuki Yasojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Nobumoto Tomioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hiroko Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Corresponding author

Correspondence to Hiroko Yamashita.

Ethics declarations

Conflict of interest

The authors have no conflict of interest.

Additional information

The original version of this article was revised: The P value of “ER (%), median (range)” was misplaced to previous row “Tumor grade 3” in Table 4 and the same was corrected.

An erratum to this article is available at http://dx.doi.org/10.1007/s12282-017-0771-2.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogiya, A., Yamazaki, K., Horii, R. et al. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer 24, 473–482 (2017). https://doi.org/10.1007/s12282-016-0730-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-016-0730-3

Keywords

Search

Navigation